Skip to main content
Advertisement

Main menu

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET

User menu

  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Molecular Pharmacology
  • Other Publications
    • Drug Metabolism and Disposition
    • Journal of Pharmacology and Experimental Therapeutics
    • Molecular Pharmacology
    • Pharmacological Reviews
    • Pharmacology Research & Perspectives
    • ASPET
  • My alerts
  • Log in
  • My Cart
Molecular Pharmacology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Fast Forward
    • Latest Articles
    • Archive
  • Information
    • Instructions to Authors
    • Submit a Manuscript
    • FAQs
    • For Subscribers
    • Terms & Conditions of Use
    • Permissions
  • Editorial Board
  • Alerts
    • Alerts
    • RSS Feeds
  • Virtual Issues
  • Feedback
  • Visit molpharm on Facebook
  • Follow molpharm on Twitter
  • Follow molpharm on LinkedIn
Research ArticleArticle

Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs

Amélie Lansiaux, Stéphane Léonce, Laurence Kraus-Berthier, Christine Bal-Mahieu, Romain Mazinghien, Sébastien Didier, Marie-Hélène David-Cordonnier, Patrick Hautefaye, Gilbert Lavielle, Christian Bailly, John A. Hickman and Alain Pierré
Molecular Pharmacology August 2007, 72 (2) 311-319; DOI: https://doi.org/10.1124/mol.107.034637
Amélie Lansiaux
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Stéphane Léonce
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Laurence Kraus-Berthier
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christine Bal-Mahieu
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Romain Mazinghien
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sébastien Didier
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Marie-Hélène David-Cordonnier
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Patrick Hautefaye
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Gilbert Lavielle
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Christian Bailly
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John A. Hickman
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Alain Pierré
Institut National de la Santé et de la Recherche Médicale U837, Université de Lille 2, Facultéde Médecine, Institut de Médecine Prédictive et Recherche Thérapeutique, Centre Oscar Lambret and Institut de Recherches sur le Cancer de Lille, Lille, France (A.L., C.B.-M., R.M., S.D., M.-H.D.-C., C.B.); and Division of Cancer Drug Discovery, Institut de Recherches Servier, Croissy sur Seine, France (S.L., L.K.-B., P.H., G.L., J.A.H., A.P.)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF
Loading

Abstract

The E-ring lactone is the Achilles' heel of camptothecin derivatives: although it is considered necessary for the inhibition of the enzyme topoisomerase I (topo1), the opening of the lactone into a carboxylate abolishes the generation of topo1-mediated DNA breaks. S38809 is a novel camptothecin analog with a stable 5-membered E-ring ketone; therefore, it lacks the lactone function. DNA relaxation and cleavage assays revealed that S38809 functions as a typical topo1 poison by stimulating DNA cleavage at T↓G sites. The activity was strongly dependent on the stereochemistry of the C-7 carbon atom that bears the hydroxy group. S38809 proved to be a potent cytotoxic agent, with a mean IC50 of 5.4 nM versus 11.6 nM for topotecan and 3.3 nM for SN38 (the active metabolite of irinotecan) on a panel of 31 human tumor cell lines. The cytotoxicity of S38809 and its ability to stabilize cleavable complexes was considerably reduced in camptothecin-resistant cells that express a mutated topo1, confirming that topo1 is its primary target. Cell death induced by topo1 poisoning requires the conversion of DNA single-strand breaks into double-strand breaks that can be detected by the formation of phosphorylated histone H2AX. In HCT116 cells, topotecan, SN38, and S38809 induced histone H2AX phosphorylation in S phase of the cell cycle, with S38809 being as potent as SN38 and 5-fold more potent than topotecan. In vivo, S38809 showed a marked antitumor activity against HCT116 xenografts. These findings open a new route for improving the pharmacological properties of camptothecin derivatives.

  • The American Society for Pharmacology and Experimental Therapeutics
View Full Text

MolPharm articles become freely available 12 months after publication, and remain freely available for 5 years. 

Non-open access articles that fall outside this five year window are available only to institutional subscribers and current ASPET members, or through the article purchase feature at the bottom of the page. 

 

  • Click here for information on institutional subscriptions.
  • Click here for information on individual ASPET membership.

 

Log in using your username and password

Forgot your user name or password?

Purchase access

You may purchase access to this article. This will require you to create an account if you don't already have one.
PreviousNext
Back to top

In this issue

Molecular Pharmacology: 72 (2)
Molecular Pharmacology
Vol. 72, Issue 2
1 Aug 2007
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover
  • Index by author
  • Back Matter (PDF)
  • Editorial Board (PDF)
  • Front Matter (PDF)
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Molecular Pharmacology article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs
(Your Name) has forwarded a page to you from Molecular Pharmacology
(Your Name) thought you would be interested in this article in Molecular Pharmacology.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Research ArticleArticle

Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs

Amélie Lansiaux, Stéphane Léonce, Laurence Kraus-Berthier, Christine Bal-Mahieu, Romain Mazinghien, Sébastien Didier, Marie-Hélène David-Cordonnier, Patrick Hautefaye, Gilbert Lavielle, Christian Bailly, John A. Hickman and Alain Pierré
Molecular Pharmacology August 1, 2007, 72 (2) 311-319; DOI: https://doi.org/10.1124/mol.107.034637

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Research ArticleArticle

Novel Stable Camptothecin Derivatives Replacing the E-Ring Lactone by a Ketone Function Are Potent Inhibitors of Topoisomerase I and Promising Antitumor Drugs

Amélie Lansiaux, Stéphane Léonce, Laurence Kraus-Berthier, Christine Bal-Mahieu, Romain Mazinghien, Sébastien Didier, Marie-Hélène David-Cordonnier, Patrick Hautefaye, Gilbert Lavielle, Christian Bailly, John A. Hickman and Alain Pierré
Molecular Pharmacology August 1, 2007, 72 (2) 311-319; DOI: https://doi.org/10.1124/mol.107.034637
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • Acknowledgments
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • eLetters
  • PDF

Related Articles

Cited By...

More in this TOC Section

  • Nelfinavir and PXR
  • P2X7 Positive Modulator Structure-Activity Relationship
  • Predicting Drug Interactions with ENT1 and ENT2
Show more Articles

Similar Articles

  • Home
  • Alerts
Facebook   Twitter   LinkedIn   RSS

Navigate

  • Current Issue
  • Fast Forward by date
  • Fast Forward by section
  • Latest Articles
  • Archive
  • Search for Articles
  • Feedback
  • ASPET

More Information

  • About Molecular Pharmacology
  • Editorial Board
  • Instructions to Authors
  • Submit a Manuscript
  • Customized Alerts
  • RSS Feeds
  • Subscriptions
  • Permissions
  • Terms & Conditions of Use

ASPET's Other Journals

  • Drug Metabolism and Disposition
  • Journal of Pharmacology and Experimental Therapeutics
  • Pharmacological Reviews
  • Pharmacology Research & Perspectives
ISSN 1521-0111 (Online)

Copyright © 2021 by the American Society for Pharmacology and Experimental Therapeutics